Welcome to our dedicated page for Fibrogen news (Ticker: FGEN), a resource for investors and traders seeking the latest updates and insights on Fibrogen stock.
FibroGen Inc (NASDAQ: FGEN) is a clinical-stage biopharmaceutical company pioneering novel therapies for oncology and anemia through innovative HIF biology and antibody-drug conjugate research. This page serves as the definitive source for verified FibroGen news and official communications, providing stakeholders with timely updates on clinical developments and corporate milestones.
Investors and industry observers will find essential information including clinical trial results, regulatory submissions, and strategic partnership announcements. Our curated feed includes earnings reports, research publications, and manufacturing updates directly impacting FibroGen's progress in bringing targeted therapies to market.
Key content categories cover advancements in the company's HIF-PH inhibitor programs for anemia management, ADC oncology candidates, and updates from global collaborations. All materials are sourced from primary corporate disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to FibroGen's latest developments. Check regularly for critical updates on pipeline progress, peer-reviewed study data, and market-moving announcements relevant to FGEN shareholders and industry analysts.
FibroGen, Inc. (NASDAQ: FGEN) has successfully completed enrollment of 372 patients in its Phase 3 clinical trial, ZEPHYRUS-2, targeting idiopathic pulmonary fibrosis (IPF). This trial, which is randomized, double-blind, and placebo-controlled, aims to assess the efficacy and safety of pamrevlumab over a 48-week period, with top-line results expected in mid-2024. The company's Chief Medical Officer expressed optimism for new treatment options for IPF patients. FibroGen is also conducting another Phase 3 trial, ZEPHYRUS-1, with data anticipated in mid-2023, furthering their commitment to addressing unmet medical needs in fibrotic diseases.
FibroGen reported 2022 total revenue of $140.7 million, down from $235.3 million in 2021. Fourth-quarter revenue was $34.4 million, compared to $16.5 million year-over-year. Roxadustat sales in China reached $82.9 million, a 74% increase from 2021, with total sales in the fourth quarter at $53.1 million, up 328%. The company anticipates key trial data releases in 2023 for treatments, including pamrevlumab and roxadustat. FibroGen has $442.7 million in cash and equivalents, sufficient to fund operations through mid-2024 without additional financing.
FibroGen (NASDAQ: FGEN) announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference held in Boston from March 5-8, 2023. The panel will focus on Respiratory/Infections and is scheduled for March 8, 2023, at 10:30 AM Eastern Time. Investors can access a live audio webcast on the FibroGen Investor webpage, with a replay available for approximately 30 days. FibroGen continues to innovate in biopharmaceuticals, focusing on therapies for conditions such as idiopathic pulmonary fibrosis and anemia associated with myelodysplastic syndromes.
FibroGen, Inc. (NASDAQ: FGEN) will release its fourth quarter and full year 2022 financial results on February 27, 2023, after market close. A conference call is scheduled for the same day at 5:00 PM Eastern Time to discuss the company’s corporate and financial performance. FibroGen focuses on developing innovative therapeutics, including Pamrevlumab for idiopathic pulmonary fibrosis and Roxadustat for anemia in chronic kidney disease. Roxadustat is already approved in several regions, while ongoing clinical trials aim to expand its applications. Investors can access the call via the company’s website.
FibroGen announced that CEO Enrique Conterno will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on February 16, 2023, at 3:40 PM ET. The event's live audio webcast will be accessible on the FibroGen Investor webpage, with a replay available for about 30 days. FibroGen focuses on developing first-in-class therapeutics, including Pamrevlumab, for treating conditions like idiopathic pulmonary fibrosis and pancreatic cancer. Their Roxadustat is already approved for treating anemia in CKD patients and is in further clinical trials.
FibroGen, Inc. (NASDAQ: FGEN) will have CEO Enrique Conterno participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8 at 1:05 PM Eastern Time. Investors can access a live audio webcast on the company's Investors webpage, with a replay available for 30 days. FibroGen focuses on developing first-in-class therapeutics, including treatments for idiopathic pulmonary fibrosis, pancreatic cancer, and anemia. Notably, Roxadustat is approved in multiple countries for CKD anemia and is in advanced trials for related conditions.
FibroGen (FGEN) reported a third-quarter 2022 net loss of $91.7 million, translating to $0.98 per share, compared to a net income of $49.8 million during the same period last year. Total revenue fell to $15.7 million from $156.0 million, impacted by a 2021 milestone payment from Astellas. However, the company secured $50 million through a non-dilutive royalty monetization deal with NovaQuest, backed by 22.5% of roxadustat royalty revenue. Roxadustat sales in China grew 29% to $17.4 million, while the MATTERHORN Phase 3 study for MDS has completed enrollment, with topline data expected in 1H 2023.
FibroGen, Inc. (FGEN) announced a strategic financing partnership with NovaQuest Capital Management, securing $50 million in non-dilutive capital. This funding aims to support the company's growth and innovation, particularly for EVRENZO™ and its late-stage pipeline. FibroGen will allocate part of the proceeds towards its pamrevlumab program, anticipating multiple pivotal Phase 3 readouts in 2023 and 2024. The agreement grants NovaQuest 22.5% of future EVRENZO™ royalties in certain regions until capped payments are reached, after which FibroGen retains full royalty rights.
FibroGen (NASDAQ: FGEN) announces that CEO Enrique Conterno will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York on November 15, 2022, at 1:50 PM ET. A live audio webcast will be accessible via the Investors section of the FibroGen website, with a replay available for 30 days.
FibroGen is a biopharmaceutical company focused on innovative therapies, including the clinical development of Pamrevlumab for treating various conditions and Roxadustat, which is approved internationally for anemia in CKD patients.
FibroGen, Inc. (NASDAQ: FGEN) will release its third quarter 2022 financial results on November 7, 2022, after market close. The company will also host a conference call with investors at 5:00 p.m. ET to discuss its corporate and financial performance. FibroGen focuses on developing innovative therapeutics, including the anti-CTGF monoclonal antibody, Pamrevlumab, and the anemia treatment, Roxadustat, which is already approved in several countries. The company is expanding its research into immuno-oncology and autoimmune therapies.
FAQ
What is the current stock price of Fibrogen (FGEN)?
What is the market cap of Fibrogen (FGEN)?
